Leadership & Strategy at Mineralys Therapeutics, Inc. (MLYS)

Add MLYS to watchlist(s)

You Should Create a Watchlist In The First Place.

Price Over Time

Profile

Company Name

Mineralys Therapeutics, Inc.

Symbol

MLYS

Currency

USD

Exchange

Nasdaq

Head Quarter

United States, Radnor

Sector

Healthcare

Industry

Biotechnology

Website

https://mineralystx.com

ISIN

US6031701013

CIK

1933414

CUSIP

603170101

UEI

-

LEI

-

Business Description

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.